Teva Pharmaceutical at center of FCPA probe

Company is the latest drug maker to be investigated for possible bribery

The world’s largest generic-drug maker is at the heart of a Foreign Corrupt Practices Act (FCPA) investigation.

In a regulatory filing last week, Israel-based Teva Pharmaceutical Industries Ltd. said that the Securities and Exchange Commission (SEC) subpoenaed it last month seeking documents related to its operations in Latin America. Business in the region accounted for $221 million in revenue in the second quarter of 2012.

Ashley Post

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.